Company: DVAX
Filing Date: 2025-04-21
Form Type: DEFC14A
Source: 0001193125-25-087127
Chunk: 15

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-04-21
Form: DEFC14A
Chunk 15
---
 biopharmaceutical company focused on therapies to treat ophthalmic
diseases, from August 2021 until the sale of the company to Viatris, Inc. in January 2023. Mr. Santel served on the board of Consonance-HFW Acquisition Corp. from December 2020 to August 2021. Mr. Santel also previously served as Executive
Chairman of Adicet Bio, Inc., a private allogeneic cell therapy oncology company, from October 2017 until its reverse merger with resTORbio, Inc. in September 2020, and from March 2018 through April 2019, as Adicet Bio’s interim Chief Executive
Officer. Mr. Santel served as Chief Executive Officer of Hyperion Therapeutics (Nasdaq GM: HPTX) from June 2008 until the sale of the company to Horizon Pharma (Nasdaq: HZNP) for $1.1 billion in May 2015, and was a member of Hyperion’s
board of directors from March 2007 through the Company’s sale. Previously, Mr. Santel was the Chief Executive Officer of CoTherix, Inc., (Nasdaq: CTRX) from January 2000 through its sale to Actelion for $419 million in January 2007.
Prior to joining CoTherix, Mr. Santel was employed by several medical device companies, including Cardiac Pathways Corporation (acquired by Boston Scientific) and Medtronic, Inc. Mr. Santel previously served on the board of directors of
Anthera Pharmaceuticals, Inc. from October 2007 to May 2012, and ChemGenex Pharmaceuticals, Inc., from December 2007 to July 2009; both publicly traded companies. Mr. Santel holds an M.S. in electrical engineering from the University of
Minnesota and a B.S.E. in biomedical engineering from Purdue University.

Mr. Santel’s many years working in the life sciences
industry, particularly as the chief executive during the sale of two such companies, provides managerial and operational perspective to the Board. Mr. Santel’s extensive experience as a healthcare chief executive officer and director would
bring to the Company strong leadership and human capital management skills, including experience managing significant mergers and acquisitions activity.

Other than as stated herein, there are no arrangements or understandings among the Deep Track Parties or any other person or persons pursuant
to which the